Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women.
Acetaminophen
/ administration & dosage
Analgesics, Non-Narcotic
/ administration & dosage
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Cyclooxygenase 2 Inhibitors
/ administration & dosage
Female
Humans
Incidence
Long Term Adverse Effects
/ diagnosis
Middle Aged
Pharmacoepidemiology
Pulmonary Embolism
/ diagnosis
Risk Assessment
/ statistics & numerical data
United States
/ epidemiology
Venous Thrombosis
/ diagnosis
NSAIDs
deep vein thrombosis
non-steroidal anti-inflammatory drugs
pharmacoepidemiology
pulmonary embolism
venous thromboembolism
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
06
07
2019
revised:
04
11
2019
pubmed:
29
1
2020
medline:
26
1
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
To evaluate the risk of venous thromboembolism (VTE, i.e. deep vein thrombosis or pulmonary embolism, or both) following new use of NSAIDs in a long-term cohort of U.S. women. We investigated initiation of coxibs and traditional NSAIDs (excluding aspirin) and incident VTE in 39 876 women enrolled in the Women's Health Study from 1993-95 and followed with yearly questionnaires until 2012. We defined initiation as the first reported use of NSAIDs for ≥4 days per month. Incident VTE was confirmed by an end point committee. We estimated hazard ratios (HRs) and risk differences (RDs, expressed as percentages) comparing NSAID initiation with non-initiation and acetaminophen initiation (active comparator) via standardization using a propensity score that incorporated age, BMI, calendar time, and relevant medical, behavioural, and socioeconomic variables updated over time. The HR (95% CI) for risk of VTE in the as treated analyses comparing initiation with non-initiation, was 1.5 (1.2, 1.8) for any NSAID, 1.3 (1.1, 1.7) for traditional NSAIDs, and 2.0 (1.3, 3.1) for coxibs, with 2-year RDs 0.11, 0.08 and 0.32, respectively. When comparing the risk of VTE after initiation of any NSAID with that after acetaminophen initiation, the HRs were 0.9 (0.6, 1.5), 0.9 (0.5, 1.5) and 1.4 (0.6, 3.4), with 2-year RDs 0.03, -0.01, and 0.13, respectively. New use of NSAIDs was associated with increased VTE risk compared with non-use, but the association was null or diminished when compared with acetaminophen initiation. Elevated VTE risks associated with NSAID use in observational studies may in part reflect different baseline risks among individuals who need analgesics and may overstate the risk patients incur compared with pharmacologic alternatives.
Identifiants
pubmed: 31990357
pii: 5716654
doi: 10.1093/rheumatology/kez653
pmc: PMC7449805
doi:
Substances chimiques
Analgesics, Non-Narcotic
0
Anti-Inflammatory Agents, Non-Steroidal
0
Cyclooxygenase 2 Inhibitors
0
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2502-2511Subventions
Organisme : NIA NIH HHS
ID : R01 AG056479
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118255
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002489
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Thromb Haemost. 2011 Jul;9(7):1326-33
pubmed: 21592304
Thromb Res. 2014 Nov;134(5):997-1003
pubmed: 25246044
Arch Intern Med. 2007 May 14;167(9):935-43
pubmed: 17502535
Circulation. 2008 Jan 1;117(1):93-102
pubmed: 18086925
BMJ. 1999 Dec 4;319(7223):1492-5
pubmed: 10582940
Sci Transl Med. 2012 May 2;4(132):132ra54
pubmed: 22553252
Lancet. 2000 Apr 15;355(9212):1295-302
pubmed: 10776741
J Clin Invest. 2006 Jan;116(1):4-15
pubmed: 16395396
Arthritis Care Res (Hoboken). 2013 Oct;65(10):1600-7
pubmed: 23666917
Comput Methods Programs Biomed. 2004 Jul;75(1):45-9
pubmed: 15158046
Nature. 2008 Feb 21;451(7181):914-8
pubmed: 18288180
Ann Intern Med. 2007 Oct 16;147(8):525-33
pubmed: 17938390
Semin Thromb Hemost. 2018 Apr;44(3):239-248
pubmed: 28946150
Arch Intern Med. 2002 May 27;162(10):1182-9
pubmed: 12020191
Circulation. 2006 Mar 28;113(12):1578-87
pubmed: 16534006
Stat Methods Med Res. 2013 Feb;22(1):70-96
pubmed: 22016461
PLoS Med. 2012;9(11):e1001335
pubmed: 23139642
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
EGEMS (Wash DC). 2016 Oct 14;4(1):1234
pubmed: 27891526
Arch Intern Med. 1998 Mar 23;158(6):585-93
pubmed: 9521222
Epidemiology. 2003 Nov;14(6):680-6
pubmed: 14569183
Occup Environ Med. 2008 Jul;65(7):481, 501-6
pubmed: 18562687
Am J Epidemiol. 2005 Nov 15;162(10):975-82
pubmed: 16207808
J Chronic Dis. 1987;40(12):1073-85
pubmed: 3680465
Rheumatology (Oxford). 2016 Jun;55(6):1099-105
pubmed: 26983451
Am J Epidemiol. 2008 Sep 15;168(6):656-64
pubmed: 18682488
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9
pubmed: 17252614
Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50
pubmed: 23723142
JAMA. 2005 Jul 6;294(1):47-55
pubmed: 15998890
JAMA. 2005 Jul 6;294(1):56-65
pubmed: 15998891
Epidemiology. 2008 Nov;19(6):766-79
pubmed: 18854702
FASEB J. 2008 Feb;22(2):383-90
pubmed: 17884974
Epidemiology. 1990 Nov;1(6):466-73
pubmed: 2090285
N Engl J Med. 2005 Mar 31;352(13):1293-304
pubmed: 15753114
JAMA Intern Med. 2015 Apr;175(4):531-9
pubmed: 25686030
Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):658-66
pubmed: 23508885
Am J Epidemiol. 2003 Nov 1;158(9):915-20
pubmed: 14585769
J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27
pubmed: 10718501
Best Pract Res Clin Haematol. 2012 Sep;25(3):235-42
pubmed: 22959540
J Natl Cancer Inst. 1999 Dec 15;91(24):2102-6
pubmed: 10601381
Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):635-42
pubmed: 21462279
Curr Epidemiol Rep. 2015 Dec;2(4):221-228
pubmed: 26954351
Circ Heart Fail. 2012 Mar 1;5(2):176-82
pubmed: 22438520
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):810-8
pubmed: 23296544
Stat Med. 2005 Oct 30;24(20):3089-110
pubmed: 16189810
Thromb Haemost. 2012 Sep;108(3):508-15
pubmed: 22782466
Rheumatology (Oxford). 2015 Apr;54(4):736-42
pubmed: 25252703
Chest. 2012 Feb;141(2 Suppl):7S-47S
pubmed: 22315257
Arch Intern Med. 2011 Sep 26;171(17):1560-9
pubmed: 21949165
Ann Rheum Dis. 2013 Jul;72(7):1182-7
pubmed: 22930596